John Seymour

Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up

Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Munoz, Alessandra Tedeschi, Andrew W Roberts, John F Seymour, Siminder Kaur Atwal, Yiling Yu, William Novotny, Eric Holmgren, Ziwen Tan, James D Hilger, Jane Huang, Constantine S Tam

Journal article  |  2020  |  Blood

Inhibitors of Bruton's tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia ..

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Joanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, Chia Sharpe, Piers Blombery, Mary Ann Anderson, Andrew W Roberts, John F Seymour, Constantine S Tam, David S Ritchie, Rachel M Koldej

Journal article  |  2020  |  Blood Advances

Combination venetoclax plus ibrutinib for the treatment of mantle cell lymphoma (MCL) has demonstrated efficacy in the relapsed or..

Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy

Farheen Mir, Federico Mattiello, Andrew Grigg, Michael Herold, Wolfgang Hiddemann, Robert Marcus, John F Seymour, Christopher R Bolen, Andrea Knapp, Tina Nielsen, Carla Casulo

Journal article  |  2020  |  American Journal of Hematology

Patients with advanced-stage follicular lymphoma (FL) who progress early after receiving first-line therapy have poor overall surv..

Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial

Ie-Wen Sim, Gelsomina L Borromeo, Claudine Tsao, Rita Hardiman, Michael S Hofman, Christian Papatziamos Hjelle, Musib Siddique, Gary JR Cook, John F Seymour, Peter R Ebeling

Journal article  |  2020  |  Journal of Clinical Oncology

PURPOSE: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent but morbid and potentially serious condition associa..

Venetoclax plus obinutuzumab therapy for front-line treatment of chronic lymphocytic leukaemia

John F Seymour

Journal article  |  2020  |  The Lancet Oncology

Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography

Michael P MacManus, Michael S Hofman, Rodney J Hicks, Belinda A Campbell, Andrew Wirth, John F Seymour, Nicole Haynes, Kate Burbury

Journal article  |  2020  |  International Journal of Radiation Oncology • Biology • Physics

PURPOSE: Patients with abscopal regressions of lymphoma after palliative involved-site radiation therapy (ISRT), detected on seque..

Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?

Mary Ann Anderson, John Francis Seymour

Journal article  |  2020  |  Leukemia & Lymphoma

Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab

Arnon P Kater, Yanwen Jiang, Brenda Chyla, John F Seymour

Journal article  |  2020  |  Haematologica: the hematology journal

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Victor S Lin, Thomas E Lew, Sasanka M Handunnetti, Piers Blombery, Tamia Nguyen, David A Westerman, Bryone J Kuss, Constantine S Tam, Andrew W Roberts, John F Seymour, Mary Ann Anderson

Journal article  |  2020  |  Blood

Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymp..

A predictive tool for early-stage CLL

Constantine S Tam, John F Seymour

Journal article  |  2020  |  Blood